Abstract
Pindolol (LB-46) is a new beta-adrenoceptor blocking agent with intrinsic sympathomimetic activity. In order to evaluate the efficacy of pindolol in the treatment of patients with supraventricular arrhythmias and propranolol-induced bronchospasm, 18 patients with paroxysmal supraventricular tachycardia, atrial fibrillation, atrial flutter, multifocal atrial tachycardia or junctional tachycardia, were treated with placebo followed by pindolol in intravenous and then oral form. Following a no-response placebo period (in all patients), intravenous pindolol converted six out of seven patients with paroxysmal supraventricular tachycardia to normal sinus rhythm. In six patients with atrial fibrillation, three reverted to normal sinus rhythm, and three remained in atrial fibrillation but with a slower ventricular response (less than 100 beats/minute). Of two patients with atrial flutter, one converted to normal sinus rhythm, while the other patient failed to respond. Both patients with junctional tachycardia and one with multifocal atrial tachycardia converted to normal sinus rhythm. Long-term oral pindolol therapy sustained these responses in most patients, as documented by serial Holter ECG studies. There was no deterioration in indices of airway resistance ( FEV 1·0 VC ) in patients treated with pindolol (both intravenously and orally), in contrast to a marked deterioration in FEV 1·0 VC in the same patients treated with propranolol. Pindolol appears to be a reasonable substitute for propranolol in patients with bronchospastic illness who require beta-blockade for control of supraventricular arrhythmias.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.